Jeffrey S. Riesmeyer

4.6k total citations
23 papers, 717 citations indexed

About

Jeffrey S. Riesmeyer is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Jeffrey S. Riesmeyer has authored 23 papers receiving a total of 717 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Surgery, 11 papers in Cardiology and Cardiovascular Medicine and 7 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Jeffrey S. Riesmeyer's work include Lipoproteins and Cardiovascular Health (8 papers), Antiplatelet Therapy and Cardiovascular Diseases (7 papers) and Diabetes Treatment and Management (6 papers). Jeffrey S. Riesmeyer is often cited by papers focused on Lipoproteins and Cardiovascular Health (8 papers), Antiplatelet Therapy and Cardiovascular Diseases (7 papers) and Diabetes Treatment and Management (6 papers). Jeffrey S. Riesmeyer collaborates with scholars based in United States, Australia and Canada. Jeffrey S. Riesmeyer's co-authors include Govinda J. Weerakkody, Giacomo Ruotolo, Kenneth J. Winters, Carolyn H. McCabe, C. Michael Gibson, Gilles Montalescot, Stephen D. Wiviott, Eugene Braunwald, Elliott M. Antman and Jeffrey W. Warmke and has published in prestigious journals such as Circulation, Blood and European Heart Journal.

In The Last Decade

Jeffrey S. Riesmeyer

23 papers receiving 696 citations

Peers

Countries citing papers authored by Jeffrey S. Riesmeyer

Since Specialization

Citations

This map shows the geographic impact of Jeffrey S. Riesmeyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey S. Riesmeyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey S. Riesmeyer more than expected).

Fields of papers citing papers by Jeffrey S. Riesmeyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey S. Riesmeyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey S. Riesmeyer. The network helps show where Jeffrey S. Riesmeyer may publish in the future.

Co-authorship network of co-authors of Jeffrey S. Riesmeyer

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey S. Riesmeyer. A scholar is included among the top collaborators of Jeffrey S. Riesmeyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey S. Riesmeyer. Jeffrey S. Riesmeyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and Safety of Tirzepatide versus Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4) 2022 ·Diabetologie und Stoffwechsel ·Stefano Del Prato, Steven E. Kahn, Imre Pávó, Govinda J. Weerakkody, Zhengyu Yang, John Doupis, Diego Aizenberg, Alan Wynne, Jeffrey S. Riesmeyer, Robert J. Heine, Russell J. Wiese, Jochen Seufert	10
2	Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes 2022 ·Cardiovascular Diabetology ·Darren K. McGuire, David D’Alessio, Stephen J. Nicholls, Steven E. Nissen, Jeffrey S. Riesmeyer, Imre Pávó, (unknown), Cory R. Heilmann, (unknown), Govinda J. Weerakkody	5
3	The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes 2020 ·Diabetes Obesity and Metabolism ·Jonathan M. Wilson, Amir Nikooienejad, Deborah A. Robins, William C. Roell, Jeffrey S. Riesmeyer, Axel Haupt, Kevin L. Duffin, Marja‐Riitta Taskinen, Giacomo Ruotolo	113
4	Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease 2020 ·JAMA Cardiology ·Rishi Puri, Steven E. Nissen, Benoît J. Arsenault, Julie St. John, Jeffrey S. Riesmeyer, Giacomo Ruotolo, Ellen McErlean, Venu Menon, Leslie Cho, Kathy Wolski, A. Michael Lincoff, Stephen J. Nicholls	85
5	Generalizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States 2019 ·Diabetes Obesity and Metabolism ·Kristina S. Boye, Matthew C. Riddle, Hertzel C. Gerstein, Reema Mody, Luis‐Emilio García‐Pérez, Chrisanthi A. Karanikas, Maureen J. Lage, Jeffrey S. Riesmeyer, Mark Lakshmanan	29
6	Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial 2019 ·Diabetes and Vascular Disease Research ·Anirudh Kumar, Divyang Patel, Kathy Wolski, A. Michael Lincoff, Sangeeta R. Kashyap, Giacomo Ruotolo, Ellen McErlean, Govinda J. Weerakkody, Jeffrey S. Riesmeyer, Stephen J. Nicholls, Steven E. Nissen, Venu Menon	10
7	Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High‐Risk Vascular Disease Treated With Statin Therapy 2019 ·Journal of the American Heart Association ·Venu Menon, Anirudh Kumar, Divyang Patel, Julie St. John, Kathy Wolski, Ellen McErlean, Jeffrey S. Riesmeyer, Govinda J. Weerakkody, Giacomo Ruotolo, Paul Cremer, Stephen J. Nicholls, A. Michael Lincoff, Steven E. Nissen	11
8	Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High‐Risk Vascular Disease: Insights From the ACCELERATE Trial 2019 ·Journal of the American Heart Association ·Anirudh Kumar, Divyang Patel, Danielle M. Brennan, Kathy Wolski, A. Michael Lincoff, Giacomo Ruotolo, Ellen McErlean, Govinda J. Weerakkody, Jeffrey S. Riesmeyer, Stephen J. Nicholls, Steven E. Nissen, Venu Menon	1
9	ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease 2018 ·JAMA Cardiology ·Steven E. Nissen, Sreekumar Pillai, Stephen J. Nicholls, Kathy Wolski, Jeffrey S. Riesmeyer, Govinda J. Weerakkody, (unknown), Ellen McErlean, Lin Li, (unknown), Giacomo Ruotolo, A. Michael Lincoff	27
10	Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial 2017 ·Atherosclerosis ·Stephen J. Nicholls, Kausik K. Ray, Christie M. Ballantyne, (unknown), Debra L. Miller, Giacomo Ruotolo, Steven E. Nissen, Jeffrey S. Riesmeyer	30
11	Navigating the Future of Cardiovascular Drug Development—Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference 2017 ·Cardiovascular Drugs and Therapy ·Thomas J. Povsic, Robert C. Scott, Kenneth W. Mahaffey, Robert O. Blaustein, Jay M. Edelberg, Martin Lefkowitz, Scott D. Solomon, Jonathan C. Fox, Kevin E. Healy, Aarif Y. Khakoo, Douglas W. Losordo, Fady I. Malik, Brett P. Monia, Rusty L. Montgomery, Jeffrey S. Riesmeyer, Gregory G. Schwartz, Steven L. Zelenkofske, Joseph C. Wu, Scott M. Wasserman, Matthew T. Roe	8
12	Efficacy and Safety of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia 2017 ·Circulation Journal ·Tamio Teramoto, Arihiro Kiyosue, (unknown), (unknown), Jeffrey S. Riesmeyer, Masahiro Murakami	2
13	A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease 2013 ·Journal of Hematology & Oncology ·Ted Wun, Denis Soulières, Andrew L. Frelinger, Lakshmanan Krishnamurti, Enrico M. Novelli, Abdullah Kutlar, Kenneth I. Ataga, Charles Knupp, (unknown), John J. Strouse, Chunmei Zhou, (unknown), Chuke Nwachuku, Joseph A. Jakubowski, Jeffrey S. Riesmeyer, Kenneth J. Winters	54
14	TRITON and Beyond: New Insights into the Profile of Prasugrel 2011 ·Cardiovascular Therapeutics ·Joseph A. Jakubowski, Jeffrey S. Riesmeyer, Sandra Close, (unknown), David Erlinge	13
15	Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON‐TIMI 38 Substudy 2011 ·The Journal of Clinical Pharmacology ·Jeffrey S. Riesmeyer, Daniel E. Salazar, Govinda J. Weerakkody, Lan Ni, Rebecca E. Wrishko, C. Steven Ernest, Junxiang Luo, Ying G. Li, David S. Small, Shashank Rohatagi, William L. Macias	41
16	A Randomized, Double-Blind, Adaptive Phase 2 Multi-Center Study of Prasugrel Compared to Placebo in Adults with Sickle Cell Disease 2011 ·Blood ·Ted Wun, Denis Soulières, Lakshmanan Krishnamurti, Abdullah Kutlar, Kenneth I. Ataga, Chunmei Zhou, (unknown), Chuke Nwachuku, Joseph A. Jakubowski, Kenneth J. Winters, Jeffrey S. Riesmeyer	2
17	Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) 2006 ·American Heart Journal ·Stephen D. Wiviott, Elliott M. Antman, C. Michael Gibson, Gilles Montalescot, Jeffrey S. Riesmeyer, Govinda J. Weerakkody, Kenneth J. Winters, Jeffrey W. Warmke, Carolyn H. McCabe, Eugene Braunwald	242
18	Safety of Abciximab Administration During PCI of Patients with Previous Stroke 2005 ·Journal of Thrombosis and Thrombolysis ·Efthymios Deliargyris, Bharathi Upadhya, Robert J. Applegate, (unknown), Michael A. Kutcher, Jeffrey S. Riesmeyer, David C. Sane	1
19	Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention 2003 ·American Journal of Health-System Pharmacy ·Patrick L. McCollam, David A. Foster, Jeffrey S. Riesmeyer	16
20	Acute hemodynamic changes during intravenous dipyridamole thallium imaging early after infarction 1989 ·American Heart Journal ·D. Douglas Miller, R. Scott, Jeffrey S. Riesmeyer, Tuhin K. Chaudhuri, Ralph Blumhardt, Charles A. Boucher, Robert A. O’Rourke	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact